Key Roles of Bim-Driven Apoptosis in Epithelial Tumors and Rational Chemotherapy

TT Tan,K Degenhardt,DA Nelson,B Beaudoin,W Nieves-Neira,P Bouillet,A Villunger,JM Adams,E White
DOI: https://doi.org/10.1016/j.ccr.2005.02.008
IF: 50.3
2005-01-01
Cancer Cell
Abstract:Defective apoptosis not only promotes tumorigenesis, but also can confound chemotherapeutic response. Here we demonstrate that the proapoptotic BH3-only protein BIM is a tumor suppressor in epithelial solid tumors and also is a determinant in paclitaxel sensitivity in vivo. Furthermore, the H-ras/mitogen-activated protein kinase (MAPK) pathway conferred resistance to paclitaxel that was dependent on functional inactivation of BIM. Whereas paclitaxel induced BIM accumulation and BIM-dependent apoptosis in vitro and in tumors in vivo, the H-ras/MAPK pathway suppressed this BIM induction by phosphorylating BIM and targeting BIM for degradation in proteasomes. The proteasome inhibitor Velcade (P-341, Bortezomib) restored BIM induction, abrogated H-ras-dependent paclitaxel resistance, and promoted BIM-dependent tumor regression, suggesting the potential benefits of combinatorial chemotherapy of Velcade and paclitaxel.
What problem does this paper attempt to address?